Chonluten

Chonluten is the bronchopulmonary entry in the Khavinson "peptide bioregulator" catalogue: a tripeptide, Glu-Asp-Gly (EDG), attributed to bronchial epithelium (Avolio et al., Int J Mol Sci 2022). Evidence tier: minimal.

A PubMed search on the name returns one experimental paper, published in 2022, co-authored by Vladimir Khavinson — whose institute originated the bioregulator concept and sells products built on it. No clinical trial of Chonluten is registered or published, and it holds no marketing authorisation in the US, EU, UK, Canada, or Australia.

That single experiment exposed human THP-1 monocytes to 100 ng/mL of five bioregulators. Chonluten raised tyrosine phosphorylation of mitogen-activated kinases and, after lipopolysaccharide challenge, suppressed TNF and IL-6 production and reduced monocyte adhesion to endothelial cells (Avolio et al., 2022). That is an anti-inflammatory readout in an immune cell line — silent about airway epithelium, mucociliary clearance, or gas exchange.

The wider hypothesis is that ultrashort peptides enter the nucleus and interact with DNA and histones to steer tissue-specific transcription (Khavinson et al., Molecules 2021 — a systematic review by the originating group).

No approved indication exists anywhere. The claims usually attached to Chonluten — that EDG "enhanced the effectiveness of standard therapy in patients with chronic bronchitis with an asthmatic component," and raised a physical-performance index under low oxygen partial pressure — appear in a 2020 review by the same group (Khavinson et al., Molecules 2020). It supplies no trial registration, participant count, comparator, or outcome definition, and the underlying reports are not indexed in PubMed.

Unapproved substances can still fall under the List's catch-all provisions, so an absent name is not a clearance. The governing ruling comes from an athlete's national anti-doping organisation.

There is no human safety dataset for Chonluten: no trial, no post-marketing series, no indexed case report. The one published experiment was in a dish, and cell culture does not generate a side-effect profile. The residual risk is an unknown one, compounded by supply — EDG is distributed by vendors outside pharmaceutical manufacturing standards, so identity, purity, and sterility of a given vial are independently unverified.

No pharmacokinetics have been published in any species: no half-life, bioavailability, or distribution data. The only published exposure value is the 100 ng/mL used in culture, which does not convert into a human dose.

Two generations of product share these names. The originals were cytomedins — peptide complexes extracted from animal organs. The synthetic short peptides, EDG among them, reproduce the active fragment of the corresponding extract, and in organotypic culture each stimulated explants of the tissue its parent extract came from (Khavinson, Bull Exp Biol Med 2001). Retail listings apply the same brand names to both.

Chonluten is also not the only bioregulator sold for this organ system; Bronchogen occupies the same claimed bronchopulmonary niche.

The complete indexed record is one 2022 in-vitro paper in a monocyte line, co-authored by the concept's originator. Everything beyond it traces to Russian-language sources or to reviews by the same group that do not report the underlying studies in checkable detail. No unaffiliated laboratory has published a replication.

Further Chonluten pages on this site:

• Chonluten benefits and areas of interest
• Chonluten side effects and safety context
• Chonluten dosing concepts (educational)
• Chonluten research and evidence overview

What is Chonluten, chemically? A three-amino-acid peptide, Glu-Asp-Gly, synthesised to mimic a fragment of a bronchial-epithelium extract.

Is there human evidence it helps breathing? None that can be verified. The respiratory claims come from a review by the developers citing no trial identifiers or sample sizes, and the one indexed experiment tested monocytes, not lung.

Is Chonluten the same as Bronchogen? No — separate molecules from the same catalogue, both marketed toward the respiratory system. Neither has an approved indication, and no head-to-head comparison exists.

Why is nearly all of this literature Russian? The programme was developed at a single St Petersburg institute and published largely in Russian-language journals or their translations, so the findings have rarely been reproduced by laboratories with no commercial stake in the result.